ArticleBlood cell therapy2026
Successful allogeneic stem cell transplantation for a patient with high titers of donor-specific antibody after multiple desensitization procedures.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 66-year-old woman who was diagnosed with acute myeloid leukemia, myelodysplasia-related underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from her human leukocyte antigen (HLA)-mismatched daughter after primary induction failure. The patient had a high donor-specific antibody (DSA) titer to the mismatched HLA antigen and received multiple desensitization treatments including rituximab, intravenous immunoglobulin, and random platelet concentrate transfusions, which resulted in a slight decrease in the DSA titer. The donor was a poor mobilizer and the patient could have received a limited number of CD34-positive cells in the PBSCT with a relatively high CD34-negative fraction. Although the graft rejection was a great concern, the patient achieved delayed but successful engraftment and complete remission. The extent of the DSA reduction was greatest after transplantation, indicating that a relatively greater number of infused CD34-negative cells had a certain effect on antagonizing the DSAs. The DSAs were detected even after engraftment, suggesting that other factors, such as HLA expression levels and HLA epitopes, might affect the engraftment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.